BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gavriilaki E, Anagnostopoulos A, Mastellos DC. Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. Front Immunol 2019;10:337. [PMID: 30891033 DOI: 10.3389/fimmu.2019.00337] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Gavriilaki E, Sakellari I, Chatzikonstantinou T, Mallouri D, Batsis I, Vardi A, Bousiou Z, Koravou EE, Masmanidou M, Touloumenidou T, Papalexandri A, Athanasiadou A, Yannaki E, Anagnostopoulos A. Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation. Hemasphere 2021;5:e487. [PMID: 33324949 DOI: 10.1097/HS9.0000000000000487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Cai Y, Deng J, Chen Z, Mei H, Tang L, Luo S, Hu Y. Brief report on the relation between complement C3a and anti dsDNA antibody in systemic lupus erythematosus. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-10936-z] [Reference Citation Analysis]
3 Gómez-de León A, Villela-martínez LM, Yáñez-reyes JM, Gómez-almaguer D. Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents. Expert Review of Hematology 2020;13:461-70. [DOI: 10.1080/17474086.2020.1750361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 McGonagle D, Bridgewood C, Ramanan AV, Meaney JFM, Watad A. COVID-19 vasculitis and novel vasculitis mimics. Lancet Rheumatol 2021;3:e224-33. [PMID: 33521655 DOI: 10.1016/S2665-9913(20)30420-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
5 Varelas C, Tampaki A, Sakellari I, Anagnostopoulos Α, Gavriilaki E, Vlachaki E. Complement in Sickle Cell Disease: Are We Ready for Prime Time? J Blood Med 2021;12:177-87. [PMID: 33790681 DOI: 10.2147/JBM.S287301] [Reference Citation Analysis]
6 Gavriilaki E, Sakellari I, Gavriilaki M, Anagnostopoulos A. A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. Int J Mol Sci 2020;21:E3886. [PMID: 32485958 DOI: 10.3390/ijms21113886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 Quinaglia T, Shabani M, Breder I, Silber HA, Lima JAC, Sposito AC. Coronavirus disease-19: The multi-level, multi-faceted vasculopathy. Atherosclerosis 2021;322:39-50. [PMID: 33706082 DOI: 10.1016/j.atherosclerosis.2021.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
8 Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals (Basel) 2020;13:E341. [PMID: 33114553 DOI: 10.3390/ph13110341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Tampaki A, Gavriilaki E, Varelas C, Anagnostopoulos A, Vlachaki E. Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. Blood Rev 2021;48:100805. [PMID: 33504459 DOI: 10.1016/j.blre.2021.100805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
11 Gavriilaki E, Sakellari I, Gavriilaki M, Anagnostopoulos A. Thrombocytopenia in COVID-19: pathophysiology matters. Ann Hematol 2021;100:2139-40. [PMID: 32683455 DOI: 10.1007/s00277-020-04183-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Merchán-del-hierro X, Camino M, Persi G, Rugilo C, Sánchez-de-paz M, Gatto E. Physiopathological implications of abnormal Arterial Spin Labeling perfusion in thrombotic microangiopathy. Thrombosis Update 2021;3:100045. [DOI: 10.1016/j.tru.2021.100045] [Reference Citation Analysis]
13 Blasco M, Guillén-Olmos E, Diaz-Ricart M, Palomo M. Complement Mediated Endothelial Damage in Thrombotic Microangiopathies. Front Med (Lausanne) 2022;9:811504. [PMID: 35547236 DOI: 10.3389/fmed.2022.811504] [Reference Citation Analysis]
14 Gavriilaki E, Brodsky RA. Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol 2020;189. [DOI: 10.1111/bjh.16783] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 47.5] [Reference Citation Analysis]
15 Holm LP, Stevens KB, Walker DJ. Pathology and Epidemiology of Cutaneous and Renal Glomerular Vasculopathy in Dogs. J Comp Pathol 2020;176:156-61. [PMID: 32359630 DOI: 10.1016/j.jcpa.2020.03.003] [Reference Citation Analysis]
16 Mejia-Vilet JM, Gómez-Ruiz IA, Cruz C, Méndez-Pérez RA, Comunidad-Bonilla RA, Uribe-Uribe NO, Nuñez-Alvarez CA, Morales-Buenrostro LE. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis. Clin Rheumatol 2021;40:2233-42. [PMID: 33170371 DOI: 10.1007/s10067-020-05499-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kulkarni A, Nasa P, Polumuru S, Singh A. Thrombotic Microangiopathy Causing Acute Kidney Injury in a COVID-19 Patient. Indian J Nephrol 2021;31:559-61. [PMID: 35068764 DOI: 10.4103/ijn.IJN_374_20] [Reference Citation Analysis]
18 Breville G, Zamberg I, Sadallah S, Stephan C, Ponte B, Seebach JD. Case Report: Severe Complement-Mediated Thrombotic Microangiopathy in IgG4-Related Disease Secondary to Anti-Factor H IgG4 Autoantibodies. Front Immunol 2020;11:604759. [PMID: 33643292 DOI: 10.3389/fimmu.2020.604759] [Reference Citation Analysis]
19 Benamu E. Infectious Risks Associated with Biologics Targeting Janus Kinase-Signal Transducer and Activator of Transcription Signaling and Complement Pathway for Inflammatory Diseases. Infect Dis Clin North Am 2020;34:271-310. [PMID: 32444011 DOI: 10.1016/j.idc.2020.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhao Y, Wei W, Liu ML. Extracellular vesicles and lupus nephritis - New insights into pathophysiology and clinical implications. J Autoimmun 2020;115:102540. [PMID: 32893081 DOI: 10.1016/j.jaut.2020.102540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Bajema IM, Chua JS, Bruijn JA. TMA: Tell Me About It! J Rheumatol 2019;46:1425-7. [PMID: 31676544 DOI: 10.3899/jrheum.190447] [Reference Citation Analysis]
22 Gavriilaki E, Sakellari I, Chatzikonstantinou T, Bousiou Z, Mallouri D, Masmanidou M, Vardi A, Koravou EE, Kika F, Touloumenidou T, Papalexandri A, Yannaki E, Batsis I, Anagnostopoulos A. Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease. Transplant Proc 2021;53:2261-6. [PMID: 34417030 DOI: 10.1016/j.transproceed.2021.07.043] [Reference Citation Analysis]
23 Gavriilaki E, Koravou E, Chatziconstantinou T, Kalpadaki C, Printza N, Ximeri M, Christoforidou A, Karavalakis G, Kaliou M, Kalaitzidou V, Tassi I, Tzellou M, Touloumenidou T, Papalexandri A, Papathanasiou M, Syrigou A, Kioumi A, Liga M, Kaiafa G, Spyridonidis A, Kapsali E, Kollios K, Mandala E, Vlachaki E, Tsirigotis P, Papadaki E, Lalayanni C, Sakellari I, Anagnostopoulos A. Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing. Thrombosis Update 2021;3:100043. [DOI: 10.1016/j.tru.2021.100043] [Reference Citation Analysis]
24 Wielosz E, Majdan M. Haematological abnormalities in systemic sclerosis. Reumatologia. 2020;58:162-166. [PMID: 32684649 DOI: 10.5114/reum.2020.96655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zheng C, Ricci J, Zhang Q, Alawieh A, Yang X, Nadig S, He S, Engel P, Jin J, Atkinson C, Tomlinson S. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol 2021;12:785229. [PMID: 34899752 DOI: 10.3389/fimmu.2021.785229] [Reference Citation Analysis]
26 Gardikioti A, Venou TM, Gavriilaki E, Vetsiou E, Mavrikou I, Dinas K, Daniilidis A, Vlachaki E. Molecular Advances in Preeclampsia and HELLP Syndrome. Int J Mol Sci 2022;23:3851. [PMID: 35409211 DOI: 10.3390/ijms23073851] [Reference Citation Analysis]
27 Newton J, Floyd L, Ponnusamy A, Anderton J. Thrombotic microangiopathy secondary to recurrent prostate cancer. Clin Nephrol Case Stud 2021;9:105-9. [PMID: 34549020 DOI: 10.5414/CNCS110609] [Reference Citation Analysis]
28 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
29 Chatzikonstantinou T, Gavriilaki M, Anagnostopoulos A, Gavriilaki E. An Update in Drug-Induced Thrombotic Microangiopathy. Front Med (Lausanne). 2020;7:212. [PMID: 32528969 DOI: 10.3389/fmed.2020.00212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
30 Wada H, Shiraki K, Matsumoto T, Shimpo H, Yamashita Y, Shimaoka M. The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome. Thrombosis Update 2020;1:100012. [DOI: 10.1016/j.tru.2020.100012] [Reference Citation Analysis]
31 Gavriilaki E, Dalampira D, Theodorakakou F, Liacos CI, Kanellias N, Eleutherakis-Papaiakovou E, Terpos E, Gavriatopoulou M, Verrou E, Triantafyllou T, Sevastoudi A, Koravou EE, Touloumenidou T, Varelas C, Papalexandri A, Sakellari I, Dimopoulos MA, Kastritis E, Katodritou E. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. J Clin Med 2022;11:3355. [PMID: 35743426 DOI: 10.3390/jcm11123355] [Reference Citation Analysis]
32 Ren Z, Perkins SJ, Love-Gregory L, Atkinson JP, Java A. Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation. Front Med (Lausanne) 2021;8:775280. [PMID: 34912830 DOI: 10.3389/fmed.2021.775280] [Reference Citation Analysis]
33 Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol 2021;14:101081. [PMID: 33862523 DOI: 10.1016/j.tranon.2021.101081] [Reference Citation Analysis]
34 Gavriilaki E, Asteris PG, Touloumenidou T, Koravou EE, Koutra M, Papayanni PG, Karali V, Papalexandri A, Varelas C, Chatzopoulou F, Chatzidimitriou M, Chatzidimitriou D, Veleni A, Grigoriadis S, Rapti E, Chloros D, Kioumis I, Kaimakamis E, Bitzani M, Boumpas D, Tsantes A, Sotiropoulos D, Sakellari I, Kalantzis IG, Parastatidis ST, Koopialipoor M, Cavaleri L, Armaghani DJ, Papadopoulou A, Brodsky RA, Kokoris S, Anagnostopoulos A. Genetic justification of severe COVID-19 using a rigorous algorithm. Clin Immunol 2021;226:108726. [PMID: 33845193 DOI: 10.1016/j.clim.2021.108726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Gavriilaki E, Sakellari I, Anyfanti P, Batsis I, Vardi A, Bousiou Z, Lazaridis A, Nikolaidou B, Zarifis I, Masmanidou M, Yiannaki E, Markala D, Anagnostopoulos A, Douma S, Gkaliagkousi E. Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation. Int J Mol Sci 2020;21:E9768. [PMID: 33371421 DOI: 10.3390/ijms21249768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Asteris PG, Gavriilaki E, Touloumenidou T, Koravou E, Koutra M, Papayanni PG, Pouleres A, Karali V, Lemonis ME, Mamou A, Skentou AD, Papalexandri A, Varelas C, Chatzopoulou F, Chatzidimitriou M, Chatzidimitriou D, Veleni A, Rapti E, Kioumis I, Kaimakamis E, Bitzani M, Boumpas D, Tsantes A, Sotiropoulos D, Papadopoulou A, Kalantzis IG, Vallianatou LA, Armaghani DJ, Cavaleri L, Gandomi AH, Hajihassani M, Hasanipanah M, Koopialipoor M, Lourenço PB, Samui P, Zhou J, Sakellari I, Valsami S, Politou M, Kokoris S, Anagnostopoulos A. Genetic prediction of ICU hospitalization and mortality in COVID‐19 patients using artificial neural networks. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17098] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
37 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Nasonov EL, Reshetnyak TM, Alekberova ZS. [Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity]. Ter Arkh 2020;92:4-14. [PMID: 32598770 DOI: 10.26442/00403660.2020.05.000697] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020;130:2152-63. [PMID: 32310222 DOI: 10.1172/JCI136094] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 36.0] [Reference Citation Analysis]
40 Hanna RM, Hasnain H, Abdelnour L, Yanny B, Burwick RM. Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy. J Int Med Res 2019;47:4027-32. [PMID: 31364428 DOI: 10.1177/0300060519864808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
41 Gavriilaki E, Sakellari I. Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: In Search of the Truth. Acta Haematol 2020;143:405-6. [PMID: 31794970 DOI: 10.1159/000504523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]